Psilocybin for Depression: From Credibility to Feasibility, What’s Missing?

Psilocybin shows promise as a transdiagnostic treatment for psychiatric disorders, with recent evidence indicating that psychedelic-assisted psychotherapy can provide significant and lasting relief from depressive symptoms. However, existing studies have limitations including small sample sizes, inadequate blinding, short follow-up periods, and highly selected treatment populations. Additional concerns involve practitioner experience, lack of standardized protocols, the legal status of psychedelics, ethical issues, and potential adverse psychological or medical effects. The authors suggest that newer evidence, more precise protocols, and policy changes may clarify psilocybin's therapeutic potential.

Study at a glance

Abstract

Psilocybin has been suggested as a promising transdiagnostic treatment strategy for a wide range of psychiatric disorders. Recent findings showed that psychedelic-assisted/”psycholitic” psychotherapy should provide significant and sustained alleviation of depressive symptoms. However, to date, there have been several study limitations (e.g., small sample sizes, blinding, limited follow-up, highly screened treatment populations) and some health/political issues, including practitioners’ experience, lack of standardized protocols, psychedelics’ legal status, ethical concerns, and potential psychological/psychopathological/medical untoward effects. The focus here is on a range of clinical and methodological issues, also aiming at outlining some possible suggestions. We are confident that newer evidence, more precise protocols, and eventual reclassification policies may allow a better understanding of the real potential of psilocybin as a transdiagnostic therapeutic molecule.